NSCLC non-metastatic
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 02/01/2020)
KEYNOTE-671 (MSD)
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) NSCLC.
PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*Lung01 Cancer Vaccine in NSCLC.
PACIFIC-4 (Astra Zeneca)
International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
LUNG005 (Merck)
Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer.
KEYNOTE-671 (MSD)
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) NSCLC.
PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*Lung01 Cancer Vaccine in NSCLC.
PACIFIC-4 (Astra Zeneca)
International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
LUNG005 (Merck)
Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer.